V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough

Cidara Therapeutics, Inc. Executive Compensation (FY24)

CDAR · Executive and director compensation, fiscal 2023 to 2024
Chief executive, fiscal 2024
◇
Jeffrey Stein
Latest say-on-pay support
=
April 21, 2025
Velarion Member: every covered company in one industry, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Cidara Therapeutics, Inc. brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
Data as of October 17, 2026Latest filing (8-K): June 20, 2025
5 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Cidara Therapeutics, Inc. brief$1,500Get the executive brief
Velarion Member, one year
115 figures on this page: 111 cited to the filing that reported them, 4 calculated from figures it prints. See the citations
What changed from fiscal 2023 to fiscal 2024
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Jeffrey Stein: $1,558,544 → $5,965,903 (282.8% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Cidara Therapeutics, Inc.'s chief executive and what were they paid?
Jeffrey Stein, President and Chief Executive Officer, received $5,965,903 in total compensation for fiscal 2024. Stein's total was 282.8% higher than the $1,558,544 reported for fiscal 2023.
What was Cidara Therapeutics, Inc.'s say-on-pay result?
The say-on-pay proposal drew 74.6% support at the meeting held April 21, 2025 for fiscal 2024.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jeffrey Stein
President and Chief Executive Officer
◇—◇◇◇—◇◇
Taylor Sandison
Former Chief Medical Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jeffrey Stein
President and Chief Executive Officer
◇——◇◇—◇◇
Leslie Tari
Chief Scientific Officer
◇—◇◇◇—◇◇
Taylor Sandison
Former Chief Medical Officer
Departed during or after this year
◇—◇◇——◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Jeffrey SteinOption◇—◇3/26/2033
RSU◇◇——
RSU◇◇——
Option◇—◇3/30/2032
Option◇—◇3/14/2034
Option◇—◇9/29/2034
Leslie TariOption◇—◇3/30/2032
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇9/29/2034
Option◇—◇3/26/2033
Option◇—◇3/14/2034
Taylor SandisonOption◇—◇9/29/2034
Option◇—◇3/30/2032
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/26/2033
Option◇—◇3/14/2034
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2024
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Daniel Burgess
◇—◇———◇
Theodore R. Schroeder
———————
Chrysa Mineo
◇—◇———◇
Carin Canale-Theakston
———————
Bonnie Bassler
◇—◇———◇
James Merson
◇—◇———◇
Laura Tadvalkar
◇—◇———◇
Ryan Spencer
◇—◇———◇
Timothy R. Franson
◇—————◇
David Gollaher
◇—————◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2024April 21, 2025=◇◇◇
2023May 28, 2024=◇◇◇
2022June 22, 2023=◇◇◇
2020June 23, 2021=◇◇◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Jeffrey Stein (President and Chief Executive Officer), FY2024 total compensation $5,965,903 (base salary $617,600) [exec_comp, SEC accession 0001610618-25-000040, filed 2025-04-25]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Cidara Therapeutics, Inc. files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Cidara Therapeutics, Inc. disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Cidara Therapeutics, Inc.'s disclosed peer group is defensible, who names Cidara Therapeutics, Inc. back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
115 figures on this page: 111 cited to the filing that reported them, 4 calculated from figures it prints.
111 cited to the filing
4 calculated from the filing

Documents cited

  1. 0001610618-25-000072
  2. 0001610618-25-000040
  3. 0001610618-24-000091
  4. 0001610618-23-000059
  5. 0001610618-21-000049
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Cidara Therapeutics, Inc. executive compensation, FY2023–FY2024.” https://intel.velarion.ai/comp/CDAR (accessed 2026).
Short form: data: Velarion

The Cidara Therapeutics, Inc. brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
5 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Cidara Therapeutics, Inc. and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy